文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

可切除初治结直肠癌肝转移患者术前循环肿瘤DNA水平与多器官复发及生存的关联:MIRACLE队列研究

Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort.
PubMed 文献 · Br J Surg · 2026-01-01

该回顾性队列研究纳入182例未接受围手术期化疗的可切除结直肠癌肝转移患者,采用mFast-SeqS法检测治疗前ctDNA水平。19%患者为ctDNA高值,其无复发生存和总生存显著缩短,1年多器官复发累积发生率显著更高,且为非独立预后因素。

要点

  • 可切除初治CRLM患者中约19%为术前ctDNA高值。
  • ctDNA高值与更短的无复发生存和总生存相关。
  • ctDNA高值者首年多器官复发累积发生率显著更高。

核心结论

  • mFast-SeqS检测可经济、微创地在治疗前识别快速多器官复发高风险的CRLM患者。

研究设计与样本

  • 回顾性队列研究,纳入182例可切除且未接受围手术期化疗的结直肠癌肝转移患者,采用mFast-SeqS法检测治疗前ctDNA非整倍体评分。

主要发现

  • 182例中34例(19%)为ctDNA高值,156例(81%)为ctDNA低值。
  • ctDNA高值组与低值组1年无复发生存率分别为29%与52%,3年总生存率分别为48%与78%(log-rank P=0.029与P<0.001)。
  • 局部治疗后首年多器官复发累积发生率在ctDNA高值组显著更高(Gray检验P<0.001)。
  • 多变量Cox回归显示非整倍体评分与RFS(HR=1.94;95%CI 1.19-3.18)、1年内多器官RFS(HR=2.56;95%CI 1.41-4.65)及3年内OS(HR=3.28;95%CI 1.79-6.01)独立相关。

临床怎么用

  • 对于可切除初治CRLM患者,术前mFast-SeqS检测ctDNA非整倍体评分有助于识别快速多器官复发高危人群,可辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Almost half of patients with colorectal liver metastases (CRLM) experience disease recurrence within one year after treatment with curative intent. To improve treatment, upfront identification of patients with CRLM at high risk of rapid disease recurrence is crucial. METHODS: In this retrospective cohort-study, pretreatment ctDNA levels were determined by the modified fast aneuploidy screening test-sequencing system (mFast-SeqS) in 182 patients with resectable CRLM who did not receive perioperative chemotherapy. Resulting aneuploidy scores were dichotomized using a predefined threshold and associated with clinical outcome. RESULTS: Of 182 analysed patients, 34 (19%) were classified as ctDNA high and 156 (81%) as ctDNA low. Recurrence-free (RFS) and overall survival (OS) were shorter in the ctDNA high versus low group, with 1-year RFS of 29% versus 52%, and 3-year OS of 48% versus 78% respectively (log-rank P = 0.029 and < 0.001 respectively). The cumulative incidence of multiorgan recurrence within the first year after local treatment was significantly higher in ctDNA-high patients (Gray's test P < 0.001). Multivariable Cox regression analysis revealed that the aneuploidy score is independently associated with RFS (HR = 1.94; 95% c.i. 1.19 to 3.18) and multiorgan RFS up to 1 year (HR = 2.56; 95% c.i. 1.41 to 4.65) and OS up to 3 years (HR = 3.28; 95% c.i. 1.79 to 6.01). CONCLUSIONS: This study shows that mFast-SeqS provides an affordable and minimally invasive test for the upfront recognition of patients with CRLM at increased risk of rapid (multiorgan) disease recurrence.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Wullaert L, van Leeuwen L, de Weerd V, et al. Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort. Br J Surg. 2026. PMID: 41967049. doi:10.1093/bjs/znaf295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。